Close

Bristol-Myers Squibb (BMY) CheckMate -057 Trial Stopped Early After Meeting Endpoint

April 17, 2015 9:01 AM EDT Send to a Friend
Bristol-Myers Squibb (NYSE: BMY) announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus docetaxel in previously treated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login